Andlauer Healthcare Group Reports 2025 First Quarter Results
Q1 2025 Summary
- Effective
March 1, 2025 , AHG entered into a joint venture (the "Joint Venture") to combine its packaging subsidiary,Nova Pack Ltd. ("Nova Pack"), withNowPac Inc. ("NowPac"), a privately-ownedToronto -based company specializing in contract packaging services for the healthcare sector; - Revenue totaled
$166.1 million , an increase of 3.1% compared to$161.1 million for the three-month period endedMarch 31, 2024 ("Q1 2024"); - Operating income was
$21.6 million , compared to$21.2 million in Q1 2024; - Net income, which includes a gain of
$5.0 million on the deconsolidation of Nova Pack, was$20.2 million , or$0.51 per share (diluted), compared to$14.9 million , or$0.35 per share (diluted), in Q1 2024; - EBITDA¹, excluding the gain on deconsolidation of Nova Pack, totaled
$40.0 million , compared to$39.6 million in Q1 2024; and - EBITDA Margin¹, excluding the gain on deconsolidation of Nova Pack, was 24.1%, compared to 24.6% in Q1 2024.
Subsequent Event
- On
April 24, 2025 , AHG announced that it had entered into a definitive arrangement agreement (the "Arrangement Agreement") with affiliates ofUPS (NYSE:UPS ) (collectively, "UPS") under whichUPS has agreed to acquire AHG via an all-cash transaction that values AHG at an equity value of approximately$2.2 billion (the "Transaction"). Under the terms of the Arrangement Agreement, shareholders of AHG will be entitled to receiveC$55.00 per share in cash. A copy of the Arrangement Agreement and a material change report regarding the Transaction are available on the Company's SEDAR+ profile at www.sedarplus.ca. - The Transaction is to be considered by shareholders at a special meeting of shareholders to be held on
June 24, 2025 . A management information circular with respect to the matters to be considered at that meeting will be filed by AHG on SEDAR+ at www.sedarplus.ca, and will been mailed to shareholders. - The completion of the Transaction will be subject to approval by the shareholders of AHG, court and applicable regulatory approvals or clearances, as well as other customary closing conditions. Subject to the satisfaction of the conditions set out in the Arrangement Agreement, the Transaction is expected to be completed in the second half of 2025.
- The Transaction is supported by
Michael Andlauer , Chief Executive Officer of the Company and the indirect holder of 53.2% of the Company's outstanding shares and 82.0% of the votes entitled to be cast to approve the Transaction.
As a result of the Transaction, the Company will no longer be holding an earnings conference call on
"Our results for the quarter reflect continued organic growth in our Canadian specialized transportation network and logistics and distribution product line. Our packaging solutions revenue for the quarter reflects just two months of operations, prior to entering into our joint venture with NowPac, but it was also performing well. This joint venture is off to a good start. Solid performance in our Canadian operations continues to be largely offset by reduced contributions from our US-based truckload businesses," said
Selected Consolidated Financial Summary
|
Three months ended
|
|
||||
($CAD 000s, except per share amounts) |
2025 |
2024 |
Variance |
|||
Revenue |
|
|
|
|||
Logistics and distribution |
42,559 |
37,918 |
12.2 % |
|
||
Packaging solutions |
4,079 |
4,942 |
(17.5) % |
|
||
Healthcare Logistics segment |
46,638 |
42,860 |
8.8 % |
|
||
Ground transportation |
108,475 |
106,388 |
2.0 % |
|
||
Air freight forwarding |
8,362 |
7,995 |
4.6 % |
|
||
Dedicated and last mile delivery |
18,803 |
17,745 |
6.0 % |
|
||
Intersegment revenue |
(16,190) |
(13,850) |
16.9 % |
|
||
Specialized Transportation segment |
119,450 |
118,278 |
1.0 % |
|
||
Total revenue |
166,088 |
161,138 |
3.1 % |
|
||
Operating expenses |
144,522 |
139,895 |
3.3 % |
|
||
Operating income |
21,566 |
21,243 |
1.5 % |
|
||
Gain on consolidation of subsidiary |
5,020 |
-- |
N/A |
|
||
Share of profit from equity-accounted joint venture, net of tax |
292 |
-- |
N/A |
|
||
Net income |
20,225 |
14,923 |
35.5 % |
|
||
Foreign currency translation adjustment |
(212) |
5,537 |
N/A |
|
||
Total comprehensive income |
20,013 |
20,460 |
(2.2) % |
|
||
Earnings per share – basic |
|
|
|
|
||
Earnings per share – diluted |
|
|
|
|
||
Earnings per share – basic, excluding gain on deconsolidation of subsidiary |
|
|
|
|
||
Earnings per share – diluted, excluding gain on deconsolidation of subsidiary |
|
|
|
|
||
Select financial metrics |
|
|
|
|
||
EBITDA¹ |
45,018 |
39,592 |
13.7 % |
|
||
EBITDA Margin¹ |
27.1 % |
24.6 % |
250 bps |
|
||
EBITDA¹, excluding gain on deconsolidation of subsidiary |
39,998 |
39,592 |
1.0 % |
|
||
EBITDA Margin¹, excluding gain on deconsolidation of subsidiary |
24.1 % |
24.6 % |
(50) bps |
|
||
|
|
|
|
|
|
|
Consolidated revenue increased by 3.1% to
Revenue for the healthcare logistics segment totaled
Revenue in the specialized transportation segment totaled
Cost of transportation and services was $84.8 million, or 51.0% of revenue, compared with $82.5 million, or 51.2% of revenue, for Q1 2024. The increase was in line with revenue and higher fuel costs. During Q1 2025, fuel rates were approximately 2.6% higher than in Q1 2024. AHG continued to carry certain idle equipment costs in its US-based truckload businesses arising from a lower volume of truckloads as the Company continues to focus on revenue quality.
Direct operating expenses were
Selling, General and Administrative Expenses were
Operating income was
Effective
Net income for Q1 2025 was
Total comprehensive income for Q1 2025 was
Earnings before interest, taxes, depreciation and amortization ("EBITDA")¹, excluding the gain on deconsolidation of Nova Pack, for Q1 2025 totaled
The Company paid a dividend (encompassing the period from
Subject to financial results, capital requirements, available cash flow, corporate law requirements and any other factors that AHG's Board of Directors may consider relevant, it is the Company's intention to declare a quarterly dividend of
On
As a result of the announcement of the Transaction, the Company's previously announced automatic share purchase plan established in connection with its current normal course issuer bid has terminated in accordance with its terms. The Arrangement Agreement restricts any further purchases under the Company's current normal course issuer bid, which will formally terminate on
As at
AHG's unaudited interim consolidated financial statements and related Management's Discussion & Analysis ("MD&A") for Q1 2025 are available on the Company's website at www.andlauerhealthcare.com and under AHG's profile on SEDAR+ at www.sedarplus.ca.
AHG is a leading and growing supply chain management company offering a robust platform of customized third-party logistics ("3PL") and specialized transportation solutions for the healthcare sector. The Company's 3PL services include customized logistics, distribution and packaging solutions for healthcare manufacturers across
This news release contains forward-looking information and forward-looking statements (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information may relate to the Company's future financial outlook and anticipated events or results and may include information regarding the Company's financial position, business strategy, growth strategies, addressable markets, budgets, operations, financial results, taxes, dividend policy, plans, objectives and expectations. Particularly, information regarding the Company's growth expectations, performance, achievements, payment of dividends, activity under the normal course issuer bid, prospects, potential acquisitions, financial targets or outlook is forward-looking information. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects", "budget", "scheduled", "estimates", "outlook", "forecasts", "projection", "prospects", "strategy", "intends", "anticipates", "believes", "commencing" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "will", "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, intentions, targets, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances. Such forward-looking statements are qualified in their entirety by the inherent risks, uncertainties and changes in circumstances surrounding future expectations which are difficult to predict and many of which are beyond the control of the Company.
Statements regarding the anticipated benefits of the Transaction for the Company, Shareholders and other stakeholders, including, plans, objectives, expectations and intentions of
Forward-looking information is necessarily based on a number of opinions, estimates and assumptions, including but not limited to those assumptions described under the heading "Cautionary Note Regarding Forward-Looking Information" in the Company's MD&A for Q1 2025. Forward-looking information is subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the risk that the Transaction will not be completed on the terms and conditions, or on the timing, currently contemplated; that the Transaction may not be completed at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, required shareholder, court and regulatory approvals and other conditions to the closing of the Transaction or for other reasons; the risk that competing offers or acquisition proposals will be made; the negative impact that the failure to complete the Transaction, for any reason, could have on the price of the subordinate voting shares of AHG or on the business of AHG; the possibility of adverse reactions or changes in business relationships resulting from the announcement or completion of the Transaction; risks relating to the Company's ability to retain and attract key personnel during and following the interim period; the possibility of litigation relating to the Transaction; credit, market, currency, operational, liquidity and funding risks generally and relating specifically to the Transaction, including changes in economic conditions, interest rates or tax rates; and those other factors discussed under the heading "Risk Factors" in the Company's annual information form dated
(1) Non-IFRS Financial Measures
This news release contains certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under IFRS. AHG uses non-IFRS measures including "EBITDA" and "EBITDA Margin". These non-IFRS measures are used to provide investors with supplemental measures of the Company's operating performance and thus highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. AHG also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. AHG management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and to determine components of management compensation.
EBITDA
AHG defines EBITDA as net income for the period before: (i) income tax expense (recovery); (ii) interest income; (iii) interest expense; and (iv) depreciation and amortization.
AHG believes EBITDA is a useful measure to assess the Company's financial performance because it provides a more relevant picture of operating results by excluding the effects of expenses that are not reflective of the Company's underlying business performance.
EBITDA Margin
AHG defines EBITDA Margin as EBITDA divided by revenue. EBITDA Margin represents a measure of the Company's profitability expressed as a percentage of revenue.
AHG believes EBITDA Margin is a useful measure to assess the Company's financial performance because it helps quantify the Company's ability to convert revenues generated from clients into EBITDA.
Reconciliation of EBITDA
($CAD 000s) |
|
|
Three Months Ended |
||
|
|
|
|
2025 |
2024 |
Net income |
|
|
|
20,225 |
14,923 |
Income tax expense |
|
|
|
5,223 |
5,445 |
Interest expense |
|
|
|
1,956 |
1,579 |
Interest income |
|
|
|
(323) |
(695) |
Depreciation and amortization |
|
|
|
17,937 |
18,340 |
EBITDA 1 |
|
|
|
45,018 |
39,592 |
Gain on deconsolidation of subsidiary |
|
|
|
(5,020) |
-- |
EBITDA 1 excluding gain on deconsolidation of subsidiary |
|
39,998 |
39,592 |
SOURCE